Heron Therapeutics Inc. (NASDAQ:HRTX) shares traded up 5.1% during mid-day trading on Tuesday . The stock traded as high as $21.87 and last traded at $21.72, with a volume of 336,434 shares. The stock had previously closed at $20.66.

Several research analysts have recently issued reports on the stock. Jefferies Group restated a “buy” rating on shares of Heron Therapeutics in a report on Monday, April 18th. Cantor Fitzgerald reiterated a “buy” rating and issued a $38.00 price target on shares of Heron Therapeutics in a report on Tuesday, August 9th. Leerink Swann set a $33.00 price target on shares of Heron Therapeutics and gave the company a “buy” rating in a report on Thursday, August 11th. Cowen and Company reiterated a “buy” rating on shares of Heron Therapeutics in a report on Saturday, July 9th. Finally, Brean Capital reiterated a “buy” rating and issued a $55.00 price target on shares of Heron Therapeutics in a report on Saturday. One analyst has rated the stock with a sell rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $47.70.

The company’s 50 day moving average price is $17.93 and its 200 day moving average price is $18.78.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.96) by $0.21. Equities research analysts expect that Heron Therapeutics Inc. will post ($4.25) earnings per share for the current year.

In other news, insider Robert Rosen sold 100,000 shares of the stock in a transaction on Wednesday, August 10th. The stock was sold at an average price of $23.30, for a total transaction of $2,330,000.00. Following the transaction, the insider now owns 102,640 shares of the company’s stock, valued at approximately $2,391,512. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Several institutional investors have recently bought and sold shares of the company. Bank of Montreal Can purchased a new position in Heron Therapeutics during the fourth quarter worth about $3,010,000. California State Teachers Retirement System increased its position in Heron Therapeutics by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 54,211 shares of the biotechnology company’s stock worth $1,447,000 after buying an additional 1,000 shares during the last quarter. Finally, Swiss National Bank purchased a new position in Heron Therapeutics during the fourth quarter worth about $1,100,000.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.